|
1.
|
Paulino AC and Okcu MF: Rhabdomyosarcoma.
Curr Probl Cancer. 32:7–34. 2008. View Article : Google Scholar
|
|
2.
|
Crist W, Gehan EA, Ragab AH, Dickman PS,
Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, et
al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol.
13:610–630. 1995.PubMed/NCBI
|
|
3.
|
Meyer WH and Spunt SL: Soft tissue
sarcomas of childhood. Cancer Treat Rev. 30:269–280. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Newton WA Jr, Soule EH, Hamoudi AB, Reiman
HM, Shimada H, Beltangady M and Maurer H: Histopathology of
childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II:
clinicopathologic correlation. J Clin Oncol. 6:67–75.
1988.PubMed/NCBI
|
|
5.
|
Sorensen PH, Lynch JC, Qualman SJ,
Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ and
Barr FG: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic
indicators in alveolar rhabdomyosarcoma: a report from the
children’s oncology group. J Clin Oncol. 20:2672–2679.
2002.PubMed/NCBI
|
|
6.
|
Loh WE Jr, Scrable HJ, Livanos E, Arboleda
MJ, Cavenee WK, Oshimura M and Weissman BE: Human chromosome 11
contains two different growth suppressor genes for embryonal
rhabdomyosarcoma. Proc Natl Acad Sci USA. 89:1755–1759. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Barr FG: Gene fusions involving PAX and
FOX family members in alveolar rhabdomyosarcoma. Oncogene.
20:5736–5746. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Fredericks WJ, Galili N, Mukhopadhyay S,
Rovera G, Bennicelli J, Barr FG and Rauscher FJ III: The PAX3-FKHR
fusion protein created by the t(2;13) translocation in alveolar
rhabdomyosarcomas is a more potent transcriptional activator than
PAX3. Mol Cell Biol. 15:1522–1535. 1995.PubMed/NCBI
|
|
9.
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Harada K, Toyooka S, Maitra A, Maruyama R,
Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna
JD and Gazdar AF: Aberrant promoter methylation and silencing of
the RASSF1A gene in pediatric tumors and cell lines. Oncogene.
21:4345–4349. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Wong IH, Chan J, Wong J and Tam PK:
Ubiquitous aberrant RASSF1A promoter methylation in childhood
neoplasia. Clin Cancer Res. 10:994–1002. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Sugawara W, Haruta M, Sasaki F, Watanabe
N, Tsunematsu Y, Kikuta A and Kaneko Y: Promoter hypermethylation
of the RASSF1A gene predicts the poor outcome of patients with
hepatoblastoma. Pediatr Blood Cancer. 49:240–249. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Wozney JM, Rosen V, Celeste AJ, Mitsock
LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA: Novel regulators
of bone formation: molecular clones and activities. Science.
242:1528–1534. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lyons KM, Hogan BL and Robertson EJ:
Colocalization of BMP 7 and BMP 2 RNAs suggests that these factors
cooperatively mediate tissue interactions during murine
development. Mech Dev. 50:71–83. 1995. View Article : Google Scholar
|
|
15.
|
Duprez DM, Coltey M, Amthor H, Brickell PM
and Tickle C: Bone morphogenetic protein-2 (BMP-2) inhibits muscle
development and promotes cartilage formation in chick limb bud
cultures. Dev Biol. 174:448–452. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Narita T, Saitoh K, Kameda T, Kuroiwa A,
Mizutani M, Koike C, Iba H and Yasugi S: BMPs are necessary for
stomach gland formation in the chicken embryo: a study using
virally induced BMP-2 and Noggin expression. Development.
127:981–988. 2000.PubMed/NCBI
|
|
17.
|
Chen D, Zhao M and Mundy GR: Bone
morphogenetic proteins. Growth Factors. 22:233–241. 2004.
View Article : Google Scholar
|
|
18.
|
Hollnagel A, Oehlmann V, Heymer J, Ruther
U and Nordheim A: Id genes are direct targets of bone morphogenetic
protein induction in embryonic stem cells. J Biol Chem.
274:19838–19845. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Horvath LG, Henshall SM, Kench JG, Turner
JJ, Golovsky D, Brenner PC, O’Neill GF, Kooner R, Stricker PD,
Grygiel JJ and Sutherland RL: Loss of BMP2, Smad8, and Smad4
expression in prostate cancer progression. Prostate. 59:234–242.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Soda H, Raymond E, Sharma S, Lawrence R,
Cerna C, Gomez L, Timony GA, Von Hoff DD and Izbicka E:
Antiproliferative effects of recombinant human bone morphogenetic
protein-2 on human tumor colony-forming units. Anticancer Drugs.
9:327–331. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kawamura C, Kizaki M and Ikeda Y: Bone
morphogenetic protein (BMP)-2 induces apoptosis in human myeloma
cells. Leuk Lymphoma. 43:635–639. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhao H, Ayrault O, Zindy F, Kim JH and
Roussel MF: Post-transcriptional down-regulation of Atoh1/Math1 by
bone morphogenic proteins suppresses medulloblastoma development.
Genes Dev. 22:722–727. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Williamson D, Missiaglia E, de Reynies A,
Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Lae M,
Freneaux P, Pritchard-Jones K, Oberlin O, Shipley J and Delattre O:
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and
molecularly indistinguishable from embryonal rhabdomyosarcoma. J
Clin Oncol. 28:2151–2158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Missiaglia E, Dalai I, Barbi S, Beghelli
S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A,
delle Fave G, Pederzoli P, Croce CM and Scarpa A: Pancreatic
endocrine tumors: expression profiling evidences a role for
AKT-mTOR pathway. J Clin Oncol. 28:245–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Esteller M: Epigenetic gene silencing in
cancer: the DNA hypermethylome. Hum Mol Genet. 16(Spec No 1):
R50–R59. 2007. View Article : Google Scholar
|
|
27.
|
Burbee DG, Forgacs E, Zochbauer-Muller S,
Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S,
Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI,
Zabarovsky E, White M and Minna JD: Epigenetic inactivation of
RASSF1A in lung and breast cancers and malignant phenotype
suppression. J Natl Cancer Inst. 93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Dammann R, Li C, Yoon JH, Chin PL, Bates S
and Pfeifer GP: Epigenetic inactivation of a RAS association domain
family protein from the lung tumour suppressor locus 3p21.3. Nat
Genet. 25:315–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Morrissey C, Martinez A, Zatyka M,
Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards
FM, Kishida T, Yao M, Schraml P, Latif F and Maher ER: Epigenetic
inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both
clear cell and papillary renal cell carcinoma. Cancer Res.
61:7277–7281. 2001.PubMed/NCBI
|
|
30.
|
Yoon JH, Dammann R and Pfeifer GP:
Hypermethylation of the CpG island of the RASSF1A gene in ovarian
and renal cell carcinomas. Int J Cancer. 94:212–217. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Dammann R, Yang G and Pfeifer GP:
Hypermethylation of the cpG island of Ras association domain family
1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3
locus, occurs in a large percentage of human breast cancers. Cancer
Res. 61:3105–3109. 2001.PubMed/NCBI
|
|
32.
|
Nakaoka T, Gonda K, Ogita T,
Otawara-Hamamoto Y, Okabe F, Kira Y, Harii K, Miyazono K, Takuwa Y
and Fujita T: Inhibition of rat vascular smooth muscle
proliferation in vitro and in vivo by bone morphogenetic protein-2.
J Clin Invest. 100:2824–2432. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Lee SJ and McPherron AC: Regulation of
myostatin activity and muscle growth. Proc Natl Acad Sci USA.
98:9306–9311. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Suryawan A, Frank JW, Nguyen HV and Davis
TA: Expression of the TGF-beta family of ligands is developmentally
regulated in skeletal muscle of neonatal rats. Pediatr Res.
59:175–179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Howe JR, Bair JL, Sayed MG, Anderson ME,
Mitros FA, Petersen GM, Velculescu VE, Traverso G and Vogelstein B:
Germline mutations of the gene encoding bone morphogenetic protein
receptor 1A in juvenile polyposis. Nat Genet. 28:184–187. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Kodach LL, Wiercinska E, de Miranda NF,
Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink
GR, van Noesel CJ, Morreau H, Hommes DW, Ten Dijke P, Offerhaus GJ
and Hardwick JC: The bone morphogenetic protein pathway is
inactivated in the majority of sporadic colorectal cancers.
Gastroenterology. 134:1332–1341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Wen XZ, Akiyama Y, Baylin SB and Yuasa Y:
Frequent epigenetic silencing of the bone morphogenetic protein 2
gene through methylation in gastric carcinomas. Oncogene.
25:2666–2673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Mahoney SE, Yao Z, Keyes CC, Tapscott SJ
and Diede SJ: Genome-wide DNA methylation studies suggest distinct
DNA methylation patterns in pediatric embryonal and alveolar
rhabdomyosarcomas. Epigenetics. 7:400–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar
|
|
40.
|
Esteller M: Cancer epigenomics: DNA
methylomes and histone-modification maps. Nat Rev Genet. 8:286–298.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Pregizer S and Mortlock DP: Control of BMP
gene expression by long-range regulatory elements. Cytokine Growth
Factor Rev. 20:509–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Chandler RL, Chandler KJ, McFarland KA and
Mortlock DP: Bmp2 transcription in osteoblast progenitors is
regulated by a distant 3′ enhancer located 156.3 kilobases from the
promoter. Mol Cell Biol. 27:2934–2951. 2007.PubMed/NCBI
|
|
43.
|
Jabbour E, Issa JP, Garcia-Manero G and
Kantarjian H: Evolution of decitabine development: accomplishments,
ongoing investigations, and future strategies. Cancer.
112:2341–2351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Cameron EE, Bachman KE, Myohanen S, Herman
JG and Baylin SB: Synergy of demethylation and histone deacetylase
inhibition in the re-expression of genes silenced in cancer. Nat
Genet. 21:103–107. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Mossman D, Kim KT and Scott RJ:
Demethylation by 5-aza-2′-deoxycytidine in colorectal cancer cells
targets genomic DNA whilst promoter CpG island methylation
persists. BMC Cancer. 10:3662010.
|
|
46.
|
Tachibana K, Takeda K and Shiraishi M:
5-Aza-2′-deoxycytidine reactivates the CDH1 gene without
influencing the methylation of the entire CpG island or histone
modification in a human cancer cell line. Proc Japan Acad.
80:342–348. 2004.
|
|
47.
|
Ghosh-Choudhury N, Woodruff K, Qi W,
Celeste A, Abboud SL and Ghosh Choudhury G: Bone morphogenetic
protein-2 blocks MDA MB 231 human breast cancer cell proliferation
by inhibiting cyclin-dependent kinase-mediated retinoblastoma
protein phosphorylation. Biochem Biophys Res Commun. 272:705–711.
2000. View Article : Google Scholar
|
|
48.
|
Beck SE, Jung BH, Fiorino A, Gomez J,
Rosario ED, Cabrera BL, Huang SC, Chow JY and Carethers JM: Bone
morphogenetic protein signaling and growth suppression in colon
cancer. Am J Physiol Gastrointest Liver Physiol. 291:G135–G145.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Wen XZ, Miyake S, Akiyama Y and Yuasa Y:
BMP-2 modulates the proliferation and differentiation of normal and
cancerous gastric cells. Biochem Biophys Res Commun. 316:100–106.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Wong GA, Tang V, El-Sabeawy F and Weiss
RH: BMP-2 inhibits proliferation of human aortic smooth muscle
cells via p21Cip1/Waf1. Am J Physiol Endocrinol Metab.
284:E972–E979. 2003.PubMed/NCBI
|
|
51.
|
Du Y and Yip H: Effects of bone
morphogenetic protein 2 on Id expression and neuroblastoma cell
differentiation. Differentiation. 79:84–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Ogata T, Wozney JM, Benezra R and Noda M:
Bone morphogenetic protein 2 transiently enhances expression of a
gene, Id (inhibitor of differentiation), encoding a
helix-loop-helix molecule in osteoblast-like cells. Proc Natl Acad
Sci USA. 90:9219–9222. 1993. View Article : Google Scholar
|
|
53.
|
Zhang S, Fantozzi I, Tigno DD, Yi ES,
Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ and
Yuan JX: Bone morphogenetic proteins induce apoptosis in human
pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol
Physiol. 285:L740–L754. 2003.PubMed/NCBI
|
|
54.
|
Iantosca MR, McPherson CE, Ho SY and
Maxwell GD: Bone morphogenetic proteins-2 and -4 attenuate
apoptosis in a cerebellar primitive neuroectodermal tumor cell
line. J Neurosci Res. 56:248–258. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
